Positive Results from NXP002 Pilot Study in Lung and Liver Fibrosis

Cambridge, UK - 31st January 2018

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces a positive outcome following innovative pilot studies in multiple fibrotic diseases for its NXP002 programme.

Download News

Back to all News